Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.
Studies in multiple pre-clinical models of cancer have demonstrated the ability of Patrys’ proprietary humanized antibody, PAT-DX1 to be taken-up and to kill cancer cells.
This confirms the successful humanization and de-immunization of 3E10-derived antibody fragments with conserved structural properties and enhanced in vitro activity.
|Maximus Resources Ltd||MXR||$0.002||100%||653,760|
|Emperor Range Group Ltd||ERX||$0.060||71.43%||8,400|
|Bass Oil Ltd||BAS||$0.003||50%||1,200,000|
|Pancontinental Oil & Gas NL||PCL||$0.004||33.33%||148,097,873|
|Strandline Resources Ltd||STA||$0.005||25%||400,000|
|UUV Aquabotix Ltd||UUV||$0.120||25%||269,478|
|NTM Gold Ltd||NTM||$0.055||22.22%||33,800|